Semaglutide is a once-weekly injectable GLP-1-RAs formulation that was approved in 2018 for the treatment of T2DM at doses up to 1 mg (8) (Product Monograph OZEMPIC ® semaglutide injection, n.d.). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.